Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and non-septic shock

Current Vascular Pharmacology

Volumn 7, Issue 2, 2009, Pages 185-197

  Rossi, Antonietta ^a   Cuzzocrea, Salvatore ^a,b   Sautebin, Lidia ^c  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

5 lipoxygenase; Adhesion molecules; Ischemia reperfusion injury; Leukotrienes; Neutrophil infiltration; Non septic shock; Septic shock

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; BW A 137 C; CELL ADHESION MOLECULE; CP 105; LEUKOTRIENE; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR; MONTELUKAST; N (4 BENZYLOXYBENZYL)ACETOHYDROXAMIC ACID; UNCLASSIFIED DRUG; VERLUKAST; ZILEUTON;

ACUTE KIDNEY FAILURE; ASTHMA; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CELLULAR DISTRIBUTION; DRUG MECHANISM; GENETIC ASSOCIATION; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTESTINE INJURY; KIDNEY INJURY; LEUKOCYTE MIGRATION; LUNG INJURY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE;

EID: 65949088595     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109787455725     Document Type: Review

References (207)

1. 4production. Proc Natl Acad Sci U S A 2006; 103: 13150-5.
2. 4synthase activities. Proc Natl Acad Sci USA 1986; 83: 857-61.
3. 4hydrolase: structural and functional properties of the active center. J Lipid Mediat 1993; 6: 1-13.
4. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568-75.
5. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 1130-7.
6. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-9.
7. 4hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38: 68-74.
8. 4synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-600.
9. 2in allergic response and parturition. Nature 1997; 390: 618-22.
10. 2in allergen-induced airway inflammation and remodelling in a mouse asthma model. J Exp Med 2007; 204: 865-77.
11. Werz O, Klemm J, Samuelsson B, Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci U S A 2000; 97: 5261-66.
12. Werz O, Burkert E, Fischer L, Szellas D, Dishart D, Samuelsson B, et al. Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J 2002; 16: 1441-3.
13. Luo M, Jones SM, Peters-Golden M, Brock TG. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc Natl Acad Sci U S A 2003; 100: 12165-70.
14. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357: 1841-54.
15. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006; 58: 375-88.
16. Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Nicosia S, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003; 55: 195-227.
17. 4: metabolism and signal transduction. Arch Biochem Biophys 2001; 385: 231-41.
18. 4in upregulation of CCR7 expression and function. Blood 2007; 109: 626-31.
19. 4receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 369-75.
20. 4receptors in rheumatoid arthritis. Autoimmun Rev 2007; 7: 12-7.
21. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421-2.
22. 4Receptors BLT1 and BLT2: Expression and Function in Human and Murine Mast Cells. J Immunol 2006; 177: 3439-47.
23. 4receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem 2005; 280: 24816-23.
24. 4receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol 2006; 176: 6254-61.
25. Rocconi RP, Kirby TO, Seitz RS, Beck R, Straughn JM Jr, Alvarez RD, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008; 15: 321-6.
26. Bäck M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci 2002; 71: 611-22.
27. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789-93.
28. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004; 279: 46129-34.
29. Hui Y, Cheng Y, Smalera I, Jian W, Goldhahn L, Fitzgerald GA, et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004; 110: 3360-6.
30. Yoshisue H, Kirkham-Brown J, Healy E, Holgate ST, Sampson AP, Davies DE. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. J Allergy Clin Immunol 2007; 119: 132-40.
31. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; 25: 4615-27.
32. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-66.
33. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998; 279: 1181-6.
34. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177-83.
35. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N. Anti-leukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007; 14: 1966-77.
36. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-43.
37. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350: 29-37.
38. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser, B, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10: 966-73.
39. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, et al. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 1996; 97: 2491-8.
40. 4plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995; 92: 517-21.
41. Avis I, Martinez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005; 65: 4181-90.
42. 4receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161: 421-8.
43. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 2003; 170: 1994-9.
44. Jiang WG, Douglas-Jones A, Mansel RE. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 275-81.
45. Nielsen CK, Ohd JF, Wikstrom K, Massoumi R, Paruchuri S, Juhas M, et al. The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. Adv Exp Med Biol 2003; 525: 201-4.
46. Golubic M, Prayson RA, Vargo L, Bondar J, Barnett GH. Increased expression of 5-lipoxygenase in glioblastoma multiforme. Adv Exp Med Biol 2003; 525: 205-8.
47. Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 2004; 24: 821-7.
48. Yoshimura R, Matsuyama M, Mitsuhashi M, Takemoto Y, Tsuchida K, Kawahito Y, et al. Relationship between lipoxygenase and human testicular cancer. Int J Mol Med 2004; 13: 389-93.
49. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis 2005; 26: 785-91.
50. Chen X, Sood S, Yang CS, Li N, Sun Z. Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention. Curr Cancer Drug Targets 2006; 6: 613-22.
51. Cuzzocrea S, Rossi A, Serraino I, Mazzon E, Di Paola R, Dugo L, et al. 5-lipoxygenase knockout mice exhibit a resistance to pleurisy and lung injury caused by carrageenan. J Leukoc Biol 2003; 73: 739-46.
52. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, et al. 5-lipoxygenase knockout mice exhibit a resistance to acute pancreatitis induced by cerulean. Immunology 2003; 110: 120-30.
53. Cuzzocrea S, Rossi A, Mazzon E, Di Paola R, Genovese T, Muia C, et al. 5-lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest 2005; 85: 808-22.
54. Mazzon E, Sautebin L, Caputi AP, Cuzzocrea S. 5-lipoxygenase modulates the alteration of paracellular barrier function in mice ileum during experimental colitis. Shock 2006; 25: 377-83.
55. Genovese T, Mazzon E, Rossi A, Di Paola R, Cannovo G, Muia C, et al. Involvment of 5-lipoxygenase in spinal cord injury. J Neuroimmunol 2005; 166: 55-64.
56. Collin M, Rossi A, Cuzzocrea S, Patel NS, Di Paola R, Hadley J, et al. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol 2004; 76: 961-70.
57. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, et al. Role of 5-lipoxygenase in the multiple organ failure induced by zymosan. Intensive Care Med 2004; 30: 1935-43.
58. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, et al. 5-lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. Shock 2003; 20: 230-6.
59. Patel NSA, Cuzzocrea S, Chatterjee PK, Di Paola R, Sautebin L, Britti A, et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 2004; 66: 2207.
60. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation - the two keystones of ischemia/reperfusion injury. Int J Cardiol 2002; 86: 41-59.
61. Di Filippo C, Rossi F, D'Amico M. Targeting polymorphonuclear leukocytes in acute myocardial infarction. Sci World J 2007; 7: 121-34.
62. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003; 26: 248-54.
63. Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A. Targets for vascular protection after acute ischemic stroke. Stroke 2004; 35: 2220-5.
64. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003; 62: 127-36.
65. Simundic AM, Basic V, Topic E, Demarin V, Vrkic N, Kunovic B, et al. Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med 2004; 27: 86-92.
66. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289: 558-68.
67. Baskaya MK, Hu Y, Donaldson D, Maley M, Rao AM, Prasad MR, et al. Protective effect of the 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. J Neurosurg 1996; 85: 112-6.
68. Zhou Y, Wei EQ, Fang SH, Chu LS, Wang ML, Zhang WP, et al. Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci 2006; 79: 1645-56.
69. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-9.
70. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76: 505-9.
71. 4production in ischemic brain. Am J Physiol 1995; 268: 1249-57.
72. Ciceri P, Rabuffetti M, Monopoli A, Nicosia S. Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br J Pharmacol 2001; 133: 1323-29.
73. Tomimoto H, Shibata M, Ihara M, Akiguchi I, Ohtani R, Budka H. A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol 2002; 104: 601-7.
74. Zhang RL, Lu CZ, Ren HM, Xiao BG. Metabolic changes of arachidonic acid after cerebral ischemia-reperfusion in diabetic rats. Exp Neurol 2003; 184: 746-52.
75. Panickar KS, Norenberg MD. Astrocytes in cerebral ischemic injury: morphological and general considerations. Glia 2005; 50: 287-98.
76. Ciccarelli R, D'Alimonte I, Santavenere C, D'Auro M, Ballerini P, Nargi E, et al. Cysteinyl-leukotrienes are released from astrocytes and increase astrocyte proliferation and glial fibrillary acidic protein via cys-LT1 receptors and mitogen-activated protein kinase pathway. Eur J Neurosci 2004; 20: 1514-24.
77. Huang XJ, Zhang WP, Li CT, Shi WZ, Fang SH, Lu YB, et al. Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation. Glia 2008; 56:27-37.
78. 4selectively increases blood-brain barrier permeability after focal ischemia in rats. J Cereb Blood Flow Metab 1991; 11: 638-43.
79. 4: role in transient cerebral ischemia of gerbils. Neurochem Res 1999; 24: 1225-32.
80. Di Gennaro A, Carnini C, Buccellati C, Ballerio R, Zarini S, Fumagalli F, et al. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J 2004; 18: 842-4.
81. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999; 56: 657-63.
82. Zhang WP, Hu H, Zhang L, Ding W, Yao HT, Chen KD, et al. Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci Lett 2004; 363: 247-51.
83. Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol Sin 2002; 23: 871-7.
84. Zhang LH, Wei EQ. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol Sin 2003; 24: 1241-7.
85. Zhang SH, Wei EQ, Zhu CY, Chen Z, Zhang SF. Protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia induced by endothelin-1 in rats. Yao Xue Xue Bao 2004; 39: 1-4.
86. Yu GL, Wei EQ, Zhang SH, Xu HM, Chu LS, Zhang WP, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 2005; 73: 31-40.
87. Yu GL, Wei EQ, Wang ML, Zhang WP, Zhang SH, Weng JQ, et al. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res 2005; 1053: 116-25.
88. Fang SH, Zhou Y, Chu LS, Zhang WP, Wang ML, Yu GL, et al. Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci Lett 2007; 412: 78-83.
89. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport 2004; 15: 2181-4.
90. Sheng WW, Li CT, Zhang WP, Yuan YM, Hu H, Fang SH, et al. Distinct roles of CysLT1 and CysLT2 receptors in oxygen glucose deprivation-induced PC12 cell death. Biochem Biophys Res Commun 2006; 346: 19-25.
91. Kitagawa K, Matsumoto M, Hori M. Cerebral ischemia in 5-lipoxygenase knockout mice. Brain Res 2004; 1004: 198-202.
92. Tsirpanlis G. Inflammation in atherosclerosis and other conditions: a response to danger. Kidney Blood Press Res 2005; 28: 211-217.
93. Kostulas K, Gretarsdottir S, Kostulas V, Manolescu A, Helgadottir A, Thorleifsson G, et al. PDE4D and ALOX5AP genetic variants and risk for Ischemic cerebrovascular disease in Sweden. J Neurol Sci 2007; 263: 113-7.
94. Hakonarson H. Role of FLAP and PDE4D in myocardial infarction and stroke: Target discovery and future treatment options. Curr Treat Options Cardiovasc Med 2006; 8: 183-92.
95. González P, Reguero JR, Lozano I, Morís C, Coto E. A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet 2007; 34: 127-30.
96. Rossoni G, Sala A, Berti F, Testa T, Buccellati C, Molta C, et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X 1005: importance of transcellular biosynthesis of cysteinil-leukotrienes. J Pharmacol Exp Ther 1996; 276: 335-41.
97. Welt K, Fitzl G, Mark B. Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural-morphometric study. Exp Toxicol Pathol 2000; 52: 27-36.
98. Takase B, Maruyama T, Kurita A, Uehata A, Nishioka T, Mizuno K, et al. Arachidonic acid metabolites in acute myocardial infarction. Angiology 1996; 47: 649-61.
99. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-6.
100. Takase B, Kurita A, Maruyama T, Uehata A, Nishioka T, Mizuno K, et al. Change of plasma leukotriene C4 during myocardial ischemia in humans. Clin Cardiol 1996; 19: 198-204.
101. 4receptors and myocardial reperfusion injury. J Pharmacol Exp Ther 1992; 260: 979-89.
102. Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44: 1845-53.
103. Jiang W, Hall SR, Moos MP, Cao RY, Ishii S, Ogunyankin KO, et al. Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 2008; 172: 592-602.
104. Sprague RS, Stephenson AH, Dahms TE, Lonigro AJ. Proposed role for leukotrienes in the pathophysiology of multiple systems organ failure. Crit Care Clin 1989; 5: 315-29.
105. Adamek A, Jung S, Dienesch C, Laser M, Ertl G, Bauersachs J, et al. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur J Pharmacol 2007; 571: 51-4.
106. King RC, Binns OA, Rodriguez F, Kanithanon RC, Daniel TM, Spotnitz WD, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69: 1681-5.
107. Anner H, Kaufman RP, Kobzik L, Valery CR, Shepro D, Hechtman HB. Pulmonary leukosequestration induced by hind limb ischemia. Ann Surg 1987; 206, 162-7.
108. Anner H, Kaufman RP, Kobzik L, Valery CR, Shepro D, Hechtman HB. Pulmonary hypertension and leukosequestration after lower torso ischemia. Ann Surg 1987; 206: 642-8.
109. Goldman G, Welbourn R, Klausner JM, Kobzik L, Valeri CR, Shepro D, et al. Mast cells and leukotrienes mediate neutrophil sequestration and lung edema after ischemia in rodents. Surgery 1992; 112: 578-86.
110. 4receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999; 104: 309-16.
111. 2inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model. Transplantation 2006; 81: 1700-7.
112. 2in an isolated rat lung model after 18 h of cold preservation. Eur J Cardiothorac Surg 2006; 29: 304-11.
113. 2receptor antagonist, FR173657, on pulmonary ischemia-reperfusion injury in dogs. J Heart Lung Transplant 2002; 21: 1022-9.
114. Klausner JM, Paterson IS, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Leukotrienes but not complement mediate limb ischemia-induced lung injury. Ann Surg 1989; 209: 462-70.
115. Shimizu N, Kita T, Aoe M, Nakata M, Miyai Y, Teramoto S. Changes in levels of arachidonic acid metabolites in blood and bronchoalveolar lavage fluid after warm ischemia-reperfusion of lung. Acta Med Okayama 1991; 45: 417-22.
116. Ishikawa F, Miyazaki S. New biodefense strategies by neutrophils. Arch Immunol Ther Exp 2005; 53: 226-33.
117. Klausner JM, Peterson IS, Goldman G, Kobzik L, Rodzen C, Lawrence R, et al. Postischemic renal injury is mediated by neutrophils and leukotrienes. Am J Physiol 1989; 256: F794-802.
118. Yu DS, Char DL, Chang SY, Ma CP. Pathogenesis of ischemia reperfusion injury of the kidney after transient renal arterial clamping in rats. J Formos Med Assoc 1998; 97: 606-13.
119. Patel NSA, Cuzzocrea S, Chatterjee PK, Di Paola R, Sautebin L, Britti D, et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 2004; 66: 220-7.
120. 4in acute renal ischemic-reperfusion injury. Proc Natl Acad Sci USA 2000; 97: 823-8.
121. Sener G, Sehirli O, Velioglu-Ogunc A, Cetinel S, Gedik N, Caner M, et al. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res 2006; 54: 65-71.
122. Homer-Vanniasinkam S, Crinnion JN, Gough MJ. Post-ischaemic organ dysfunction: a review. Eur J Vasc Endovasc Surg 1997; 14: 195-203.
123. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion: a review. Acta Cir Bras 2005; 20: 336-43.
124. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Ann Rev Pharmacol Toxicol 1993; 33: 71-90.
125. Zingarelli B, Squadrito F, Inoculano MP, Altavilla D, Bussolino F, Campo GM, et al. Platelet activating factor in splanchnic artery occlusion shock. Eur J Pharmacol 1992; 222: 13-9.
126. Carey C, Siegfried MR, Ma XL, Weyrich AS, Lefer AM. Antishock and endothelial protective actions of a NO donor in mesenteric ischemia and reperfusion. Circ Shock 1992; 38: 209-16.
127. 4antagonist in splanchnic ischemia and reperfusion in rats. Am J Physiol 1991; 261: G191-8.
128. Souza DG, Pinho V, Cassali GD, Poole S, Teixeira MM. Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat. Eur J Pharmacol 2002; 440: 61-9.
129. Mangino MJ, Murphy MK, Anderson CB. Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury. J Pharmacol Exp Ther 1994; 269: 75-81.
130. 4regulation of splanchnic blood flow during ischemia. Am J Surg 1994; 167, 566-9.
131. Mangino MJ, Mangino JE, Kotadia B, Sielczak M. Effects of the 5-lipoxygenase inhibitor A-64077 on intestinal hypothermiv organ preservation injury. J Pharmacol Exp Ther 1997; 281: 950-6.
132. 4receptor antagonist. Br J Pharmacol 2003; 140: 71-80.
133. 4. J Appl Physiol 2008; 104: 1161-6.
134. Cutrn JC, Perrelli MG, Cavalieri B, Peralta C, Rosell Catafau J, Poli G. Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. Free Radic Biol Med 2002; 33: 1200-8.
135. Serracino-Inglott F, Virlos IT, Habib NA, Williamson RC, Mathie RT. Differential nitric oxide synthase expression during hepatic ischemia reperfusion. Am J Surg 2003; 185: 589-95.
136. Hur GM, Ryu YS, Yun HY, Jeon BH, Kim YM, Seok JH, et al. Hepatic ischemia/reperfusion in rats induces iNOS gene transcription by activation of NFkappaB. Biochem Biophys Res Commun 1999; 261: 917-22.
137. Kawachi S, Hines IN, Laroux FS, Hoffman J, Bharwani S, Gray L, et al. Nitric oxide synthase and postischemic liver injury. Biochem Biophys Res Commun 2000; 276: 851-4.
138. Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia reperfusion injury. Am J Surg 2001; 181: 160-6.
139. Jaeschke H. Molecular mechanisms of hepatic ischemia reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284: G15-26.
140. Meyer K, Brown MF, Zibari G, Panes J, McMillan RW, McDonald JC, et al. ICAM-1 upregulation in distant tissues after hepatic ischemia/ reperfusion: a clue to the mechanism of multiple organ failure. J Pediatr Surg 1998; 33: 350-3.
141. Jaeschke H, Farhood A. Kupffer cell activation after no-flow ischemia vs hemorrhagic shock. Free Radic Biol Med 2002; 33: 210-9.
142. Uehara N, Ormstad K, Orning L, Hammarström S. Characteristics of the uptake of cysteine-containing leukotrienes by isolated hepatocytes. Biochim Biophys Acta 1983; 732: 69-74.
143. 4by peripheral blood mononuclear cells in patients with fulminant hepatitis. J Gastroenterol Hepatol 1993; 8: 228-31.
144. Titos E, Claria J, Bataller R, Bosch-Marce M, Gines P, Jimenez W, et al. Hepatocyte derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000; 119: 794-805.
145. Quiroga J, Prieto J. Liver cytoprotection by prostaglandins. Pharmacol Ther 1993; 58: 67-91.
146. Sinclair S, Levy G. Eicosanoids and the liver. Ital J Gastroenterol 1990; 22: 205-13.
147. 4in the pathogenesis of hepatic ischemia-reperfusion injury in the rat. Prostaglandins Leuk Essent Fatty Acids 1992; 45: 113-19.
148. Takamatsu Y, Shimada K, Chijiiwa K, Kuroki S, Yamaguchi K, Tanaka M. Role of leukotrienes on hepatic ischemia/reperfusion injury in rats. J Surg Res 2004; 119: 14-20.
149. 4synthase expression and activities of ischemia-reperfusion-injured liver in rats. J Surg Res 2007; 140: 36-44.
150. Matsui N, Fukuishi N, Fukuyama Y, Yasui Y, Akagi M. Protective effect of the 5-lipoxygenase inhibitor ardisiaquinone A on hepatic ischemia-reperfusion injury in rats. Planta Med 2005; 71: 717-20.
151. Bone RC. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). J Am Med Assoc 1995; 273: 155-6.
152. Van Deventer S. Antibody to endotoxin in the treatment of gram-negative sepsis. J Am Med Assoc 1992; 267: 2325-6.
153. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003; 29: 530-8.
154. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23: 1638-52.
155. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Trzeciak S, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Annal Emerg Med 2006; 48: 28-54.
156. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
157. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170: 1435-44.
158. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, De Backer D, et al. Year in review in intensive care medicine, 2006. II Infections and sepsis, haemodynamics, elderly, invasive and noninvasive mechanical ventilation, weaning, ARDS. Intensive Care Med 2007; 33: 214-29.
159. Evans TW, Smithies M. ABC of intensive care: organ dysfunction. Br Med J 1999; 318: 1606-9.
160. Curzen NP, Griffiths MJ, Evans TW. Role of the endothelium in modulating the vascular response to sepsis. Clin Sci (Lond) 1994; 86: 359-74.
161. Botha AJ, Moore FA, Moore EE, Kim FJ, Banerjee A, Peterson VM. Postinjury neutrophil priming and activation: an early vulnerable window. Surgery 1995; 118: 358-65.
162. Cochrane CG. Immunologic tissue injury mediated by neutrophilic leukocytes. Adv Immunol 1968; 9: 97-162.
163. Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med 1995; 21: 277-85.
164. Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol 1994; 56: 672-86.
165. Leone M, Boutiere B, Camoin-Jau L, Albanese J, Horschowsky N, Mege JL, et al. Systemic endothelial activation is greater in septic than in traumatic-traumatic-haemorrhagic shock but does not correlate with endothelial activation in skin biopsies. Crit Care Med 2002; 30: 808-14.
166. Ogura H, Tanaka H, Koh T, Fujima S, Nakamori Y, Hosotsubo H, et al. Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. J Trauma 2004; 56: 823-30.
167. Seekamp A, Jochum M, Ziegler M, Van Griensven M, Martin M, Regel G. Cytokines and adhesion molecules in elective and accidental
168. Morlion BJ, Torwesten E, Kuhn KS, Puchstein C, Fürst P. Cysteinyl-leukotriene generation as a biomarker for survival in the critically ill. Crit Care Med 2000; 28: 3655-8.
169. Anderson MR, Blumer JL. Prognostic markers in sepsis: the role of leukotrienes. Crit Care Med 2000; 28: 3762-3.
170. Baenkler M, Leykauf M, John S. Functional analysis of eicosanoids from white blood cells in sepsis and SIRS. J Physiol Pharmacol 2006; 57: 25-33.
171. Tran HS, Quinn JV, Puc MM, Woolley DS, Puglisi RN, Slotman GJ. The cardiovascular hemodynamics and leukotriene kinetics during prostacyclin and anti-prostacyclin antibody infusions in septic shock. Shock 2000; 13: 478-84.
172. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
173. Van der Poll T. Immunotherapy of sepsis. Lancet Inf Dis 2001; 1: 165-74.
174. Benjamim CF, Canetti C, Cunha FQ, Kunkel SL, Peters-Golden M. Opposing and hierarchical roles of leukotrienes in local innate immune vs vascular responses in a model of sepsis. J Immunol 2005; 174: 1616-20.
175. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004; 279: 46129-34.
176. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645-55.
177. Dahlen SE, Bjork J, Hedqvist P, Arfors KE, Hammarstrom S, Lindgren JA, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981; 78: 3887-91.
178. 4. Prostaglandins 1981; 21: 637-48.
179. Ball HA, Cook JA, Wise WC, Halushka PV. Role of thromboxane, prostaglandins and leukotriene in endotoxic and septic shock. Intensive Care Med 1986; 12: 116-26.
180. Azab AN, Kaplanski J. Involvement of eicosanoids in the hypothermic response to lipopolysaccharide during endotoxemia in rats. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 67-75.
181. László F, Whittle BJ. Colonic microvascular integrity in acute endotoxaemia: interactions between constitutive nitric oxide and 5-lipoxygenase products. Eur J Pharmacol 1995; 277: R1-3.
182. Can C, Cinar MG, Ulker S, Evinc A, Kosay S. Effects of MK-886, a leukotriene biosynthesis inhibitor, in a rabbit model of endotoxic shock. Eur J Pharmacol 1998; 350: 223-8.
183. Sibelius U, Grandel U, Buerke M, Kiss L, Klingenberger P, Heep M, et al. Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escherichia coli hemolysin in perfused rat hearts. Crit Care Med 2003; 31: 683-8.
184. Quinn JV, Slotman GJ. Platelet-activating factor and arachidonic acid metabolites mediate tumor necrosis factor and eicosanoid kinetics and cardiopulmonary dysfunction during bacteremic shock. Crit Care Med 1999; 27: 2485-94.
185. Singh VP, Patil CS, Kumar M, Kulkarni SK. Effect of 5-lipoxygenase inhibitor against lipopolysaccharide-induced hypothermia in mice. Indian J Exp Biol 2005; 43: 1150-55.
186. Stephenson AH, Lonigro AJ, Hyers TM, Webster RO, Fowler AA. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis 1988; 138: 714-9.
187. Chang SW, Westcott JY, Pickett WC, Murphy RC, Voelkel NF. Endotoxin-induced lung injury in rats: role of eicosanoids. J Appl Physiol 1989; 66: 2407-18.
188. 4in sheep. Prostaglandins 1985; 30: 419-34.
189. Ichinose F, Zapol WM, Sapirstein A, Ullrich R, Tager AM, Coggins K, et al. Attenuation of hypoxic pulmonary vasoconstriction by endotoxemia requires 5-lipoxygenase in mice. Circ Res 2001; 88: 832-38.
190. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000; 174: 21-34.
191. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, et al. The role of the liver in the response to LPS: experimental and clinical findings. Endotoxin Res 2002; 8: 319-27.
192. Iredale JP. Regulating hepatic inflammation: pathogen-associated molecular patterns take their toll. Hepatology 2003; 37: 979-82.
193. Oda M, Han JY, Nakamura M. Endothelial cell dysfunction in microvasculature: relevance to disease processes. Clin Hemorheol Microcirc 2000; 23: 199-211.
194. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gasterointest Liver Physiol 2002; 283: G256-G65.
195. Chen LC, Gordon RE, Laskin JD, Laskin DL. Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia. Exp Mol Pathol 2007; 83: 311-26.
196. Faist E, Baue AE, Dittmer H, Heberer G. Multiple organ failure in poly-trauma patients. J Trauma 1983; 23: 775-87.
197. Marshall WG, Dimick AR. Natural history of major burns with multiple subsystem failure. J Trauma 1983; 23: 102-5.
198. Saffle JR, Sullivan JJ, Tuohig GM. Multiple organ failure in patients with thermal injury. Crit Care Med 1993; 21: 1673-83.
199. Aikowa N, Shinozawa Y, Ishibiki K. Clinical analysis of multiple organ failure in burned patients. Burns 1987; 13: 103-9.
200. Allardyce DB. Incidence of necrotising pancreatitis and factors related to mortality. Am J Surg 1987; 154: 295-9.
201. Baue AE, Guthrie D. Multiple system failure and circulatory support. Jpn J Surg 1983; 13: 69-85.
202. Shayevitz JR, Miller C, Johnson KJ, Rodriguez JL. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of non septic origin. Shock 1995; 4: 389-96.
203. Rao TS, Currie JL, Shaffer AF, Isakson PC. In vivo characterization of zymosan-induced mouse peritoneal inflammation. J Pharmacol Exp Ther 1994; 269: 917-25.
204. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997: 185: 1065-75.
205. 4hydrolase-deficient mice. J Immunol 1999; 163: 6810-9.
206. 1receptor antagonist montelukast. Prostaglandins Other Lipid Mediat 2007; 83: 257-67.
207. Kalsotra A, Zhao J, Anakk S, Dash PK, Strobel HW. Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution. J Cereb Blood Flow Metab 2007; 27: 963-74.